| Name | Title | Contact Details |
|---|
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.
Cosmo Bio USA is a company that provides quality life science products from leading Japanese manufacturers to laboratories, research institutes, life science education and testing organizations throughout North America.
Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through the development and commercialization of Allergy Immunotherapy products and services. Our purpose is to enable people with allergies to live normal lives. With more than 1,400 employees worldwide, a presence in 75 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy.